156 related articles for article (PubMed ID: 34844557)
1. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department.
Santeri S; Peter AA; Kristiina N; Jesper EO; Harri H
BMC Emerg Med; 2021 Nov; 21(1):149. PubMed ID: 34844557
[TBL] [Abstract][Full Text] [Related]
2. Value of the soluble urokinase-type plasminogen activator receptor as a predictor of prognosis in patients attended in hospital emergency departments.
Herrero-Puente P; Eugen-Olsen J; Ferreras Amez JM; Gamazo Del Río J; Prieto-García B; de Las Heras-Vallelado A; Arribas Entrala B; González Del Castillo J
Emergencias; 2024 Jan; 36(1):17-24. PubMed ID: 38318738
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
Chenevier-Gobeaux C; Lemarechal H; Doumenc B; Peschanski N; Claessens YE; Borderie D; Ray P
Clin Biochem; 2021 Jun; 92():19-24. PubMed ID: 33662350
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O
Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986
[TBL] [Abstract][Full Text] [Related]
5. suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19.
Altintas I; Eugen-Olsen J; Seppälä S; Tingleff J; Stauning MA; El Caidi NO; Elmajdoubi S; Gamst-Jensen H; Lindstrøm MB; Rasmussen LJH; Kristiansen KT; Rasmussen C; Nehlin JO; Kallemose T; Hyppölä H; Andersen O
Biomark Insights; 2021; 16():11772719211034685. PubMed ID: 34421295
[TBL] [Abstract][Full Text] [Related]
6. Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department.
Bengaard AK; Iversen E; Kallemose T; Juul-Larsen HG; Rasmussen LJH; Dalhoff KP; Andersen O; Eugen-Olsen J; Houlind MB
Br J Clin Pharmacol; 2022 Feb; 88(4):1679-1690. PubMed ID: 34242432
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic power of soluble urokinase plasminogen activator receptor (suPAR) for short-term mortality in patients seen in Emergency Departments due to infections].
Rubio Díaz R; de Rafael González E; Martín Torres E; Valera Núñez E; López Martos AM; Melguizo Melguizo D; Picazo Perea MP; López García PJ; Fuentes Bullejos P; Chafer Rudilla M; Carretero Gómez JF; Julián-Jiménez A
Rev Esp Quimioter; 2022 Feb; 35(1):50-62. PubMed ID: 34859658
[TBL] [Abstract][Full Text] [Related]
8. Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.
Stauning MA; Altintas I; Kallemose T; Eugen-Olsen J; Lindstrøm MB; Rasmussen LJH; Gamst-Jensen H; Nehlin JO; Andersen O; Tingleff J
J Emerg Med; 2021 Sep; 61(3):298-313. PubMed ID: 34092446
[TBL] [Abstract][Full Text] [Related]
9. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.
Alstrup M; Meyer J; Schultz M; Rasmussen LJH; Rasmussen LS; Køber L; Forberg JL; Eugen-Olsen J; Iversen K
World J Surg; 2019 Mar; 43(3):780-790. PubMed ID: 30390135
[TBL] [Abstract][Full Text] [Related]
10. Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients.
Holstein RM; Seppälä S; Kaartinen J; Hongisto M; Hyppölä H; Castrén M
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743359
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
Godtfredsen NS; Jørgensen DV; Marsaa K; Ulrik CS; Andersen O; Eugen-Olsen J; Rasmussen LJH
Respir Res; 2018 May; 19(1):97. PubMed ID: 29783959
[TBL] [Abstract][Full Text] [Related]
12. Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial.
Schultz M; Rasmussen LJH; Kallemose T; Kjøller E; Lind MN; Ravn L; Lange T; Køber L; Rasmussen LS; Eugen-Olsen J; Iversen K
Scand J Trauma Resusc Emerg Med; 2019 Apr; 27(1):43. PubMed ID: 30975178
[TBL] [Abstract][Full Text] [Related]
13. The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma - a retrospective cohort study.
Håkansson KEJ; Rasmussen LJH; Godtfredsen NS; Tupper OD; Eugen-Olsen J; Kallemose T; Andersen O; Ulrik CS
Respir Res; 2019 Nov; 20(1):258. PubMed ID: 31730462
[TBL] [Abstract][Full Text] [Related]
14. suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients.
Meyer J; Alstrup M; Rasmussen LJH; Schultz M; Ladelund S; Haupt TH; Tingleff J; Iversen K; Eugen-Olsen J
Scand J Trauma Resusc Emerg Med; 2018 Feb; 26(1):11. PubMed ID: 29391054
[TBL] [Abstract][Full Text] [Related]
15. Ability of combined soluble urokinase plasminogen activator receptor to predict preventable emergency attendance in older patients in Japan: a prospective pilot study.
Mitsunaga T; Ohtaki Y; Yajima W; Sugiura K; Seki Y; Mashiko K; Uzura M; Takeda S
PeerJ; 2022; 10():e14322. PubMed ID: 36353607
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
Sörensen NA; Nikorowitsch J; Neumann JT; Rübsamen N; Goßling A; Hartikainen TS; Blankenberg S; Westermann D; Zeller T; Karakas M
Clin Res Cardiol; 2019 Dec; 108(12):1386-1393. PubMed ID: 30989318
[TBL] [Abstract][Full Text] [Related]
17. Pre-hospital suPAR, lactate and CRP measurements for decision-making: a prospective, observational study of patients presenting non-specific complaints.
Jousi M; Mäkinen M; Kaartinen J; Meriläinen L; Castrén M
Scand J Trauma Resusc Emerg Med; 2021 Oct; 29(1):150. PubMed ID: 34656150
[TBL] [Abstract][Full Text] [Related]
18. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III).
Schultz M; Rasmussen LJH; Andersen MH; Stefansson JS; Falkentoft AC; Alstrup M; Sandø A; Holle SLK; Meyer J; Törnkvist PBS; Høi-Hansen T; Kjøller E; Jensen BN; Lind M; Ravn L; Kallemose T; Lange T; Køber L; Rasmussen LS; Eugen-Olsen J; Iversen KK
Scand J Trauma Resusc Emerg Med; 2018 Aug; 26(1):69. PubMed ID: 30153859
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor and procalcitonin for risk stratification in patients with a suspected infection in the emergency department: a prospective cohort study.
Tong-Minh K; Endeman H; Ramakers C; Gommers D; van Gorp E; van der Does Y
Eur J Emerg Med; 2023 Oct; 30(5):324-330. PubMed ID: 37288566
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
